11:58:14 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2023-11-16 Kvartalsrapport 2023-Q3
2023-08-31 Kvartalsrapport 2023-Q2
2023-05-11 Kvartalsrapport 2023-Q1
2023-04-18 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-12 Kvartalsrapport 2022-Q1
2022-04-22 Ordinarie utdelning LYTIX 0.00 NOK
2022-04-21 Årsstämma 2022
2022-02-17 Bokslutskommuniké 2021


ListaMERK Equities
Lytix Biopharma är ett bioteknikbolag i kliniskt stadium som utvecklar nya cancerimmunterapier. Bolagets teknik bygger på forskning inom antimikrobiella peptider, ett försvar riktade mot patogener. Lytix Biopharmas huvudprodukt, LTX-315, är en onkolytisk peptid med syftet att personalisera immunterapi. Bolaget bedriver sin forskning och verksamhet i Oslo.
2022-02-10 09:12:42
Lytix Biopharma AS will release its fourth quarter 2021 results on Thursday, 17
February at 7 am CEST. The results will be presented in a webcast with CEO
Øystein Rekdal, CDO Graeme Currie and CFO Gjest Breistein at 2:30 pm CEST.

The presentation and subsequent Q&A session will be held in English and may be
viewed live by registering here: Lytix Biopharma Q4 webcast 17.02.2022
A recording of the presentation will after the presentation be made available on

For more information, please contact:
Øystein Rekdal, CEO: +47 975 73 358
Gjest Breistein, CFO: +47 952 60 512

Lytix in brief: Based in Oslo, Norway, Lytix Biopharma is a clinical stage
biotech company developing novel cancer immunotherapies, an area within cancer
therapy that is aimed at activating the patient's immune system to fight cancer.
The Company's technology is based on pioneering research in "host defense
peptides" - nature's first line of defense towards foreign pathogens. Lytix
Biopharma's lead product, LTX-315, is a first-in-class oncolytic molecule
representing a new and superior in situ therapeutic vaccination principle to
boost anti-cancer immunity, with the potential to be the ideal combination
partner with other types of immunotherapy. LTX-315 target cancer cells and
disintegrate their cell membranes, causing immunogenic cell death and release of
a patient's tumor specific antigens. This mode of action allows cytotoxic T
cells to recognize, infiltrate, and attack cancer cells. The Company was listed
on Euronext Growth in Oslo in June 2021, following a private placement covered
by investors such as PBM Capital, a US based, healthcare-focused investment